<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02468141</url>
  </required_header>
  <id_info>
    <org_study_id>KCRD_SJDBT_2015</org_study_id>
    <nct_id>NCT02468141</nct_id>
  </id_info>
  <brief_title>Effect of Sipjeondaebo-tang for Cancer Related Anorexia in Cancer Patients</brief_title>
  <official_title>Effect of Sipjeondaebo-tang for Cancer Related Anorexia in Cancer Patients: A Randomized Double Blinded Placebo Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine efficacy and safety of Sipjeondaebo-tang for Cancer patients suffering from
      anorexia after chemotherapy. Sipjeondaebo-tang will be administered for 4 weeks, 3 times per
      day after a meal. Changes of FAACT scale, Anorexia VAS, Weight, BMI, Clinical laboratory test
      such as ACTH, Cortisol, Chrelin, IL-6, ESR, CRP will be measured and analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Functional Assessment of Anorexia/Cachexia Therapy - Anorexia Cachexia Subscale</measure>
    <time_frame>4 weeks</time_frame>
    <description>Function scores as measured by the likert scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FAACT scale</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Cancer-related Problem/Condition</condition>
  <arm_group>
    <arm_group_label>SJDBT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herbal medicine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SJDBT</intervention_name>
    <description>Sipjeondaebo-tang</description>
    <arm_group_label>SJDBT group</arm_group_label>
    <other_name>Sipjeondaebotang</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ages 20 to 80 years

          -  Individuals who are suffering from cancer-associated anorexia

          -  Patients within 1 month after completion of chemotherapy

          -  No plan for additional chemotherapy or radiotherapy

          -  Anorexia visual analogue scale (VAS) ≥ 40/100mm

          -  Qi deficiency scale ≥ 30 or Blood deficiency scale ≥ 30

          -  Neutrophil ≥ 1,500/㎕, platelet ≥ 100,000/㎕

          -  Total bilirubin lower than upper limit of normal (1.2 mg/㎗)

          -  ALT, AST lower than 2-fold the upper limit of normal

          -  Creatinine lower than 1.5 fold the upper limit of normal(1.09 mg/㎗)

          -  Written informed consent for participation in the trial

        Exclusion Criteria:

          -  Patient impossible to oral intake

          -  Patient 5 years after cancer diagnosis

          -  ECOG performance status score &gt; 3

          -  Patient with dementia, delirium, depression

          -  Patient who complain of more than 7 points when we use Numeric Rating Scale, which can
             affect appetite or calorie intake, within 2 weeks of screening

          -  Patient with diseases which can influence on appetite (such as hypoadrenalism, etc)

          -  Patient who are taking appetizers (such as megestrol acetate, corticosteroids,
             thalidomide)

          -  Women who has possibility of a pregnancy

          -  Others who are judged not to be appropriate to study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunhoo Cheon, Master</last_name>
    <role>Study Director</role>
    <affiliation>Institute of Safety and Efficiency Evaluation for Korean Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dunsan Korean Medicine Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>302-869</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Seong-Gyu Ko</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Juzentaihoto</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

